Documents
719900
Resomer® RG 504 H, Poly(D,L-lactide-co-glycolide)
acid terminated, lactide:glycolide 50:50, Mw 38,000-54,000
Recommended Products
Quality Level
form
amorphous
feed ratio
lactide:glycolide 50:50
mol wt
Mw 38,000-54,000
degradation timeframe
<3 months
viscosity
0.45-0.60 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)
transition temp
Tg 46-50 °C
storage temp.
2-8°C
InChI
1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2
InChI key
LCSKNASZPVZHEG-UHFFFAOYSA-N
Related Categories
1 of 4
This Item | 719927 | 719919 | 739944 |
|---|---|---|---|
| viscosity 0.45-0.60 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer) | viscosity 0.71-1.0 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer) | viscosity 0.14-0.22 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer) | viscosity 0.45-0.60 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer) |
| transition temp Tg 46-50 °C | transition temp Tg 49-55 °C | transition temp Tg 42-46 °C | transition temp Tg 46-50 °C |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C |
| feed ratio lactide:glycolide 50:50 | feed ratio lactide:glycolide 75:25 | feed ratio lactide:glycolide 75:25 | feed ratio lactide:glycolide 50:50 |
| mol wt Mw 38,000-54,000 | mol wt Mw 76,000-115,000 | mol wt Mw 4,000-15,000 | mol wt Mw 38,000-54,000 |
Application
It can be used to preparepolymer nanospheres for encapsulating CuO, to form stimuli-responsivemultifunctional nanocarriers.
Legal Information
related product
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.
Difficulty Finding Your Product Or Lot/Batch Number?
How to Find the Product Number
Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (Example: T1503).
Example:
Additional examples:
705578-5MG-PW
PL860-CGA/SHF-1EA
MMYOMAG-74K-13
1000309185
enter as 1.000309185)
Having trouble? Feel free to contact Technical Service for assistance.
How to Find a Lot/Batch Number for COA
Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.
Aldrich Products
For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').
For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').
For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.
Not Finding What You Are Looking For?
In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.
Customers Also Viewed
Articles
Interest in utilizing biodegradable polymers for biomedical applications has grown since the 1960s.
The world of commercial biomaterials has stagnated over the past 30 years as few materials have successfully transitioned from the bench to clinical use. Synthetic aliphatic polyesters have continued to dominate the field of resorbable biomaterials due to their long history and track record of approval with the U.S. Food and Drug Administration (FDA).
Aliphatic polyesters such as polylactide, poly(lactide-co-glycolide) and polycaprolactone, as well as their copolymers, represent a diverse family of synthetic biodegradable polymers that have been widely explored for medical uses and are commercially available.
Immunosuppressive tumor-associated myeloid cells (TAMC) are responsible for glioblastoma (GBM) resistance to immunotherapies and existing standard of care treatments. This mini-review highlights recent progress in implementing nanotechnology in advancing TAMC-targeted therapies for GBM.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service